117th Congress · House
TRANSPLANT Act of 2021
Subjects: Advisory bodies · Blood and blood diseases · Cell biology and embryology · Congressional oversight · Government studies and investigations · Health programs administration and funding · Medical research · Organ and tissue donation and transplantation
In plain language
- House bill in the 117th Congress.
- Modifies and reauthorizes through FY2026 the C.W.
- House passed it on Apr 15, 2021 (substantive).
Official summary (Congressional Research Service)
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2021 or the TRANSPLANT Act of 2021 This bill modifies and reauthorizes through FY2026 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. The bill also requires the Department of Health and Human Services to conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments. In addition, the Government Accountability Office must report on the regenerative medicine workforce.
View this measure on congress.gov
Roll-call votes on this measure
- substantiveApr 15, 2021 · House · Passed
On Motion to Suspend the Rules and Pass — H R 941 — TRANSPLANT Act